ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

-Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumors

-Trial overview presented at ESMO Congress 2023 (Madrid, Spain)

-Dose levels 1 and 2 successfully completed

ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced an update on the ongoing Phase 1a/b trial of its lead program IOS-1002 in Australia. The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.

Following completion of the initial two dose levels, dose levels will now be escalated to determine dose-limiting toxicities (DLTs), with the DLT period defined as 4 weeks after cycle 1, day 1 infusion. A second cohort of IOS-1002 in combination with pembrolizumab will be initiated after completion of the fifth dose level. Following completion of the dose-escalation portion of the trial, a tumor-specific cohort expansion in up to six different solid tumor settings will be initiated to further evaluate IOS-1002 as a monotherapy and in combination with pembrolizumab. In pre-clinical models, the combination of IOS-1002 with a PD-1 checkpoint blockade inhibitor demonstrated enhanced anti-tumor activity.

Primary endpoints of the current Phase 1a, first-in-human, open-label, non-randomized, multicenter study will be the safety and tolerability of IOS-1002, as well as establishment of dose-limiting toxicity, multiple ascending dose, and recommended Phase 1b dose. Secondary endpoints include preliminary anti-tumor efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002. The Phase 1a/b trial is expected to enroll over 120 patients.

"We are pleased that the trial is progressing as planned," said Christoph Renner, M.D., CMO and co-founder of ImmunOs Therapeutics. “IOS-1002 is a first-in-class compound that targets multiple immune checkpoints, making it a unique activator of both the innate and the adaptive immune system, and we hope it can fill a significant gap in current cancer therapy and help patients with advanced solid tumors."

###

About IOS-1002

IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 for the treatment of advanced solid tumors. As a multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) targeting multiple immune checkpoints, IOS-1002 enhances the immune response of diverse sets of both innate and adaptive immune cells and trigger anti-tumor activity.

About ImmunOs Therapeutics AG

ImmunOs Therapeutics AG is pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Company has identified specific HLA molecules known to activate the immune system and is utilizing these HLA molecules as the backbone of novel therapies capable of stimulating both the innate and the adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs’ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses. ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.

The Company is supported by leading international investors including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, BioMed Partners, Schroder Adveq, Mission BioCapital, GL Capital, PEAK6, Fiscus and Redalpine. ImmunOs is located in Schlieren, Switzerland, and Gaithersburg, MD, USA.

For more information, please visit www.immunostherapeutics.com

Company Contact

ImmunOs Therapeutics AG

Wagistrasse 18

8952 Schlieren (Zurich Area), Switzerland

info@immunostherapeutics.com

Media Inquiries

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

info@akampion.com

Tel. +49 40 88 16 59 64 /

Tel. +49 30 23 63 27 68